S303 Red Blood Cells (RBCs) + Conventional, untreated Red Blood Cells (RBCs)
Phase 2Completed 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Focus: Assess Post Infusion Viability of S303 RBCs
Conditions
Focus: Assess Post Infusion Viability of S303 RBCs
Trial Timeline
Oct 1, 2012 → Nov 1, 2014
NCT ID
NCT01711346About S303 Red Blood Cells (RBCs) + Conventional, untreated Red Blood Cells (RBCs)
S303 Red Blood Cells (RBCs) + Conventional, untreated Red Blood Cells (RBCs) is a phase 2 stage product being developed by Cerus for Focus: Assess Post Infusion Viability of S303 RBCs. The current trial status is completed. This product is registered under clinical trial identifier NCT01711346. Target conditions include Focus: Assess Post Infusion Viability of S303 RBCs.
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01711346 | Phase 2 | Completed |
Competing Products
2 competing products in Focus: Assess Post Infusion Viability of S303 RBCs
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Nascobal nasal spray (cyanocobalamin, USP) + Vitamin B12-ratiopharm N, injection solution | Swedish Orphan Biovitrum | Phase 1 | 32 |
| S-303 Red Blood Cells (RBCs) - Test + Conventional, untreated red blood cells (RBCs) - Control | Cerus | Phase 3 | 69 |
Other Products from Cerus
Traditional Cryoprecipitate + Pathogen-Reduced CryoprecipitateApproved
77
Pathogen-Reduced Plasma + Crystalloid SolutionsApproved
77
S-303 Treated Red Blood Cells (RBCs) + Conventional, untreated Red Blood CellsPhase 3
69
S-303 Red Blood Cells (RBCs) - Test + Conventional, untreated red blood cells (RBCs) - ControlPhase 3
69
Autologous apheresis Platelet Components, prepared with the INTERCEPT Blood System for Platelets. + Autologous apheresis Conventional untreated Platelet ComponentsPhase 2
44